Oramed Pharmaceuticals (ORMP) Competitors

Sana Biotechnology (NASDAQ:SANA) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, community ranking, analyst recommendations, profitability and valuation.

Do insiders & institutionals have more ownership in SANA or ORMP?

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 31.1% of Sana Biotechnology shares are held by company insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has better earnings & valuation, SANA or ORMP?

Oramed Pharmaceuticals has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$283.26M	-$1.40	-2.47
Oramed Pharmaceuticals	$1.34M	71.00	$5.53M	$0.11	21.45

Does the MarketBeat Community favor SANA or ORMP?

Oramed Pharmaceuticals received 299 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 73.00% of users gave Oramed Pharmaceuticals an outperform vote while only 60.61% of users gave Sana Biotechnology an outperform vote.

Company	Underperform	Outperform
Sana Biotechnology	Outperform Votes 20 60.61%	Underperform Votes 13 39.39%
Oramed Pharmaceuticals	Outperform Votes 319 73.00%	Underperform Votes 118 27.00%

Does the media refer more to SANA or ORMP?

In the previous week, Sana Biotechnology had 34 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 38 mentions for Sana Biotechnology and 4 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.59 beat Sana Biotechnology's score of 0.46 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	8 Very Positive mention(s)	5 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oramed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is SANA or ORMP more profitable?

Oramed Pharmaceuticals' return on equity of -7.27% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-84.22%	-44.97%
Oramed Pharmaceuticals	N/A	-7.27%	-6.20%

Do analysts prefer SANA or ORMP?

Sana Biotechnology presently has a consensus price target of $14.25, suggesting a potential upside of 311.85%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe Sana Biotechnology is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more volatility & risk, SANA or ORMP?

Sana Biotechnology has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.

Summary

Oramed Pharmaceuticals beats Sana Biotechnology on 10 of the 16 factors compared between the two stocks.